GlycoMimetics Receives Extension Notice from Nasdaq Regarding Minimum Bid Price ComplianceOn December 19, 2024, GlycoMimetics, Inc. (NASDAQ: GLYC) disclosed in an 8-K filing with the Securities and Exchange Commission that it had received an extensio

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read GlycoMimetics’s 8K filing here.

About GlycoMimetics

GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.